Merck & Co., Inc. (NYSE:MRK)

CAPS Rating: 3 out of 5

A global research-driven pharmaceutical company that discovers, develops, manufactures and markets a range of innovative products to improve human and animal health.

Results 1 - 20 of 415 : 1 2 3 4 5 6 7 8 9 10 Next »

Recs

0
Member Avatar IBDvalueinvestin (99.64) Submitted: 4/13/2014 7:27:48 PM : Outperform Start Price: $56.22 MRK Score: -0.35

HEP C

Recs

0
Member Avatar EPS100Momentum (72.08) Submitted: 4/11/2014 11:33:02 AM : Outperform Start Price: $56.37 MRK Score: -0.70

50% Cure rate for Hep C phase II trials. This feels like Blockbuster in the making. Market will price it in quickly. Anther 25% to 50% gains potential here.

Recs

0
Member Avatar bwann (49.36) Submitted: 4/10/2014 9:14:39 PM : Outperform Start Price: $55.48 MRK Score: +0.85

Merck has steadily been refocusing strategic objectives to fit in within sound business practices. They are done wrestling down Vioxx settlements, they are selling off non-core businesses, and they are doubling down on R&D. Investors love R&D.

Recs

0
Member Avatar afewgoodstocks11 (32.28) Submitted: 3/22/2014 12:15:43 AM : Outperform Start Price: $39.63 MRK Score: +13.35

Div. (Yield) $1.76 (3.2%)
Current Yield . . . . . . 4.44%

Recs

0
Member Avatar happygigging (< 20) Submitted: 1/22/2014 10:50:31 AM : Outperform Start Price: $51.13 MRK Score: +10.42

New drugs are coming.

Recs

0
Member Avatar cmrk3 (54.13) Submitted: 1/18/2014 7:13:26 PM : Outperform Start Price: $51.47 MRK Score: +10.08

It is a 2014 Dog of the Dow

Recs

0
Member Avatar Reddragyn (70.54) Submitted: 1/14/2014 4:07:14 PM : Outperform Start Price: $52.24 MRK Score: +8.09

Dog Test

Recs

0
Member Avatar ncmantle (27.89) Submitted: 1/13/2014 3:39:36 PM : Outperform Start Price: $52.72 MRK Score: +5.58

Latest FDA approval of new Melanoma treatment great news.

Recs

1
Member Avatar ErnestBludger (86.53) Submitted: 8/28/2013 5:34:05 PM : Outperform Start Price: $45.78 MRK Score: +10.83

It helps people - as well as making money - as shareholders, we have a chance to participate in the work that MRK does in saving lives with the drugs that we as shareholders fund. MRK presently has the chance to assist a man with 3 young kids to access the PD1 melanoma drug. Go and look at the link below to see what our company (and our investments) can do to really change lives. As a company, we need to do this! http://www.change.org/petitions/merck-bms-save-locky-s-dad-provide-nick-auden-access-to-the-pd1-drug-on-a-compassionate-basis#share

Recs

1
Member Avatar Gr8BigBoom (94.46) Submitted: 8/17/2013 12:12:12 AM : Outperform Start Price: $46.26 MRK Score: +10.95

We live in a country were a 15 year old kid can find a cure for cancer in his dads garage, yet these mega-multi billion dollar international companies just can't seem to figure it out.

The fact is these companies have figured it out and the fact is you make far more money stringing a cancer patient along with the constant threat of death than you ever could just healing them. When you have such control and power over the environment your business operates the risk level is very low.
The greatest threat is from other countries coming in to the U.S. and people with cancer leaving to seek treatment elsewhere. I for sure wouldn't stick around this bear trap if I had cancer but being I don't and this is investing, well, you get the point.

Recs

1
Member Avatar rwpunc (69.80) Submitted: 7/26/2013 3:02:25 AM : Outperform Start Price: $46.83 MRK Score: +11.19

I see potential in the markets of their alzheimer's drug along with their diabetes treatment drug. I believe revenue will continue to be an industry leader for the next 5 years and earnings per share shall remain consistently solid.

Recs

0
Member Avatar pavlos1971 (99.68) Submitted: 6/14/2013 8:40:05 PM : Outperform Start Price: $47.10 MRK Score: +7.81

I decided that Perlmutter plus the anti-PD1 drug candidates were good enough to ease (in part) my major concerns about this company's future. I own LT calls and stock in RL and my bet is that MRK will be better than LLY; so far it works out rather well.

Recs

1
Member Avatar Flygal5 (98.80) Submitted: 6/3/2013 11:34:48 AM : Outperform Start Price: $46.58 MRK Score: +12.06

Drug pipeline is paying off. Wish the progress has come sooner but so many will be helped by the breakthrough in skin cancer treatment.

Recs

0
Member Avatar PrInAl (< 20) Submitted: 5/31/2013 6:04:46 PM : Outperform Start Price: $47.25 MRK Score: +7.10

The pharmacy business is not going anyplace. The company has opportunely announced an enormous buyback plan, recently including $5B worth of stock from Goldman Sachs so the dividends paid out decrease while available cash should improve. Downside is protected somewhat by a dividend yield closer to 4% than 3%.

Merck, or Mr.K, has to deal with patent expirations on products, but so do all its competitors. Its pipeline is robust, however.

Recs

0
Member Avatar jollyviking30 (40.13) Submitted: 5/30/2013 4:28:26 PM : Outperform Start Price: $45.32 MRK Score: +13.36

Never ever bet against MRK ! They always pull something out of their hat! Love this management team.

Recs

0
Member Avatar IfHeDiesHeDies (83.34) Submitted: 4/8/2013 7:23:46 PM : Outperform Start Price: $44.16 MRK Score: +10.25

A6++

Recs

1
Member Avatar jd8019 (81.69) Submitted: 3/3/2013 5:53:01 PM : Outperform Start Price: $41.05 MRK Score: +16.37

Merck sells it's drugs internationally. Most importantly to developing nations.

Recs

0
Member Avatar scrubs62074 (87.73) Submitted: 2/19/2013 3:52:20 PM : Outperform Start Price: $40.34 MRK Score: +19.98

Dow 30 stock bouncing on 200 DMA

Recs

0
Member Avatar JorgeAura (< 20) Submitted: 2/2/2013 4:42:13 PM : Underperform Start Price: $39.59 MRK Score: -20.36

Dowjones in maximums.

Recs

0
Member Avatar Marlonito9 (< 20) Submitted: 11/4/2012 7:58:59 PM : Underperform Start Price: $44.53 MRK Score: -8.49

This company will really conquer the S&P 500 performance. This weeks for sure.

Featured Broker Partners


Advertisement